Clinical

Immunotherapy and cellular therapy

4 papers and 0 abstracts co-authored by Raphael E. Szalat. Current lab members are shown in bold.

Papers 4

2026
Tailoring Therapy for Frail and Elderly Myeloma Patients
George T, Szalat RE
The Cancer Journal32(5)DOI: Tailoring Therapy for Frail and Elderly Myeloma Patients PubMed: Tailoring Therapy for Frail and Elderly Myeloma Patients
2026
When ICAN(S) Becomes ICAN’T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading
Ferri GM, Frank A, Li D, …, Szalat RE, …, Bell BN
Clinical Lymphoma Myeloma and Leukemia26(1):e77-e82DOI: When ICAN(S) Becomes ICAN’T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading PubMed: When ICAN(S) Becomes ICAN’T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading
2025
Teclistamab therapy for refractory type 1 cryoglobulinemia
Battaglini J, Henderson J, Sanchorawala V, Szalat R
Haematologica110(8):1891-1893DOI: Teclistamab therapy for refractory type 1 cryoglobulinemia PubMed: Teclistamab therapy for refractory type 1 cryoglobulinemia
2020
Genomic Instability in Multiple Myeloma
Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ
Trends in Cancer6(10):858-873DOI: Genomic Instability in Multiple Myeloma PubMed: Genomic Instability in Multiple Myeloma